Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Specific Use-results Study of IMJUDO Intravenous Infusion 25 mg, 300 mg / IMFINZI Intravenous Infusion 120 mg, 500 mg All Patient Investigation in Patients With Unresectable Hepatocellular Carcinoma

NCT05667064 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05667064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05667064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Specific Use-results Study of IMJUDO Intravenous Infusion 25 mg, 300 mg / IMFINZI Intravenous Infusion 120 mg, 500 mg All Patient Investigation in Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 9, 2023
Completion date
July 21, 2025
Enrollment
1,200 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma